BioMarin Pharmaceutical Inc. (BIT:1BMRN)

Italy flag Italy · Delayed Price · Currency is EUR
49.66
-0.62 (-1.23%)
At close: Jun 6, 2025, 5:30 PM CET
-29.58%
Market Cap 9.55B
Revenue (ttm) 2.73B
Net Income (ttm) 484.70M
Shares Out n/a
EPS (ttm) 2.50
PE Ratio 19.69
Forward PE 12.56
Dividend n/a
Ex-Dividend Date n/a
Volume 1,040
Average Volume 355
Open 50.06
Previous Close 50.28
Day's Range 49.66 - 51.24
52-Week Range 49.66 - 84.04
Beta n/a
RSI 35.16
Earnings Date Aug 1, 2025

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company’s products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NA... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1996
Employees 3,040
Stock Exchange Borsa Italiana
Ticker Symbol 1BMRN
Full Company Profile

Financial Performance

In 2024, BioMarin Pharmaceutical's revenue was $2.85 billion, an increase of 17.97% compared to the previous year's $2.42 billion. Earnings were $426.86 million, an increase of 154.62%.

Financial numbers in USD Financial Statements

News

There is no news available yet.